Combined Supplementary Figures from IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils
Trotter, TN; Shuptrine, CW; Tsao, L-C; Marek, RD; Acharya, C; Wei, J-P; Yang, X-Y; Lei, G; Wang, T; Lyerly, HK; Hartman, ZC
<p>SF1: IL-26 protein or mRNA expression in human cell lines and clinical samples; SF2: Single-cell profiling of CD4+ TH17 cells in TNBC patients; SF3: Confirmation of IL-26 knockdown in MDA-MB-231 cells; SF4: In vitro proliferation and in vivo metastasis of IL-26 knockdown MDA-MB-231 cells; SF5: Gene expression profiling of IL-26 knockdown MDA-MB-231 tumors; SF6: IL-26 knockdown in SUM159 and MDA-MB-468 cells and in vitro phenotyping; SF7: Western blot confirmation of IL-26 knock-in E0771 cells and IL-26 upregulation after growth in vivo; SF8: IL-26 knock-in E0771 tumors progress more rapidly than control in an immune competent setting; SF9: Stat3 activation by IL-26 is dependent on human IL10RB and IL20RA; SF10: DNA-bound IL-26 elicits inflammatory signaling in human and mouse immune cells; SF11: Confirmation of mouse neutrophil enrichment; SF12: Confirmation of Anti-Ly6G antibody depletion of mouse neutrophils; SF13: Inflammatory cytokine expression in MDA-MB-231 parental and MDA-MB-231 LM2 lung-metastatic subclone; SF14: CRISPR knockdown of IL-6, IL-8, and Cxcl1 in MDA-MB-231 LM2 CRISPR 3x cell lines/lung metastases and correlation of CRISPR 3x primary tumor volume with metastasis; SF15: IL-26 signature and Neutrophil enrichment score are significantly correlated in METABRIC dataset; SF16: T cell ELISPOT response to IL-26 vaccination in vivo.</p>
